ÍøºìºÚÁÏ

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of…

Investigator

Karen Daily

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor…

Investigator

Karen Daily

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2* early breast cancer with intermediate-high or high risk for disease recurrence who completed…

Investigator

Karen Daily

Status

Accepting Candidates

Ages

18 Years - 130 Years

Sexes

All